Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Amr Morsy
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 14.3yrs |
| CEO ownership | 2.2% |
| Management average tenure | less than a year |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
CEO
Amr Morsy
Dr. Amr Abdallah Morsy serves as Chief Executive Officer at Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (formerly known as Rameda Pharmaceutical) and its Executive Direc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | no data | no data | 2.23% EGP 151.1m | |
| Group Finance Director | less than a year | no data | no data | |
| COO & Executive Director | less than a year | no data | 0.21% EGP 14.1m | |
| Head of Mergers & Acquisitions and Investor Relations | no data | no data | no data | |
| Internal Audit | less than a year | no data | no data | |
| Head of Human Resources | less than a year | no data | no data |
Experienced Management: RMDA's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 14.3yrs | no data | 2.23% EGP 151.1m | |
| COO & Executive Director | 6.3yrs | no data | 0.21% EGP 14.1m | |
| Independent Non-Executive Director | 6.3yrs | no data | no data | |
| Non-Executive Vice Chairman | 14.3yrs | no data | 0.00053% EGP 35.9k | |
| Non-Executive Chairman of the Board | 14.3yrs | no data | 0.00053% EGP 35.9k | |
| Non-Executive Director | 9.3yrs | no data | no data | |
| Non-Executive Director | 9.3yrs | no data | no data | |
| Non-Executive Director | 7.3yrs | no data | no data | |
| Independent Non-Executive Director | 2.2yrs | no data | no data | |
| Non-Executive Director | 2.6yrs | no data | no data |
Experienced Board: RMDA's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 04:16 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ahmed Rashad | Beltone Financial |
| Marina Mikhail | CI Capital Research |
| Ahmed Moataz | EFG-Hermes Research |